Table 2. Logistic regression model of ERCC1 and IGCCCG classification associated with the insensitivity to cisplatin-based chemotherapy in patients with ns-TGCTs.
| Odds ratio | 95% Confidence interval | P-value | |
|---|---|---|---|
|
Bivariate analysis | |||
|
ERCC1 IHC presence | |||
| Positive | 2.37 | (0.97–5.77) | 0.05 |
| Negative |
1 |
|
|
|
IGCCCG classification | |||
| Good prognosis | 0.01 | (0–0.12) | <0.001 |
| Intermediate prognosis | 0.26 | (0.09–0.74) | <0.001 |
| Poor prognosis |
1 |
|
|
|
Multivariate analysis | |||
|
ERCC1 IHC presence | |||
| Positive | 2.95 | (0.97–8.97) | 0.05 |
| Negative |
1 |
|
|
|
IGCCCG classification | |||
| Good prognosis | 0.01 | (0–0.11) | <0.001 |
| Intermediate prognosis | 0.241 | (0.08–0.70) | <0.001 |
| Poor prognosis | 1 | ||
Abbreviations: ERCC1= excision repair cross-complementation group 1; IGCCCG classification=International Germ Cell Cancer Collaborating Group classification; IHC=immunohistochemistry; ns-TGCTs=non-seminomatous testicular germ cell tumours.